This information was published on 2020-02-04T08:44:01 for IP Right Registration Published.
| Field | Value |
| (210) | 2030454 (IR 1483177) |
| (220) |
05 Jun 2019
|
| (300) |
EM, 21 Dec 2018, 018003752
|
| (500) |
The applicant has advised that the words in the Mark have no meaning in English
|
| (511) (510) |
Class 5
Radiopharmaceutical preparations for use in oncology, namely radiopharmaceuticals containing Gallium-68 for treating and diagnosing tumours; Gallium-68 compounds, including 68-Ga chlorides; Gallium-68 for use in the field of targeted radionuclide therapy to diagnose cancers, in particular prostate cancer and neuroendocrine tumours; Gallium-68 compounds, including 68-Ga peptide chelates, in particular 68-Ga-Dotatoc and 68-Ga-Dotatate, 68-Ga salts, in particular 68-Ga chlorides; Gallium-68 for use as radiotracers in pet scans or combined pet/ct scans. Class 10 Ge-68/Ga-68 radionuclide generators for pharmaceutical purposes as source of radionuclides being positron emitters in the field of Positron Emission Tomography - Computed Tomography (PET/CT). Class 42 Scientific and technological services and research on radiopharmaceutical products, namely 68-Ga products for use in medicine for third parties, namely services relating to radiopharmaceuticals for the therapy and diagnosis of diseases and services relating to radiopharmaceuticals coupled to somatostatin analogues for the diagnosis and treatment of tumours. Class 44 Pharmaceutical advice in relation to radiopharmaceutical products, namely 68-Ga products for use in medicine for third parties, namely advice in relation to radiopharmaceuticals for the therapy and diagnosis of diseases, in particular tumour diseases; advice in relation to radiopharmaceuticals coupled to somatostatin analogues and advice in relation to the manufacture of personalised radiopharmaceutical products containing 68-Ga for use in medicine. |
| (540) | GEGANT |
| (550) | Word |
| (730) |
ITG Isotope Technologies Garching GmbH
|
Find out more about publications on the About page.